Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Alice B. Gottlieb*, Vibeke Strand, Mitsumasa Kishimoto, Philip Mease, Diamant Thaçi, Julie Birt, Chin H. Lee, Catherine L. Shuler, Chen Yen Lin, Dafna D. Gladman

*Corresponding author for this work
5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)'. Together they form a unique fingerprint.

Medicine & Life Sciences